Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma

February 16, 2021 Auto Bot Clinical Trials, Exelixis, Metastatic, patients, Report, results 0

Shots:

  • The P-II SWOG S1500/PAPMET trial involves assessing cabometyx (60 mg, qd with dose reductions to 40 & 20mg ), crizotinib, and savolitinib vs sunitinib in a ratio (1:1:1:1) for patients with advanced or metastatic PRCC
  • The results demonstrated significant improvement in PFS. The trial met its 1EP’s shows mPFS (9.0 mos. vs 5.6 mos.); ORR (23% vs 4%) mOS (20.0 mos. vs 16.4 mos.)
  • The findings were presented at the 2021 ASCO GU and simultaneously published in The Lancet

Click here ­to­ read full press release/ article | Ref: Exelixis | Image: Exelixis

The post Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma first appeared on PharmaShots.